| Publication date | Communities | Collections | Article title | Author(s) | Journal/Conference |
|---|---|---|---|---|---|
| 23 Jul 2015 | BMRC | Institute of Molecular and Cell Biology | TLR3 agonist and Sorafenib combinatorial therapy promotes immune activation and controls hepatocellular carcinoma progression | Victor Ho, Tong Seng Lim, Justin Lee, Jeffrey Steinberg, Radoslaw Szmyd, Muly Tham, Jadegoud Yaligar, Philipp Kaldis, Jean-Pierre Abastado, Valerie Chew | Oncotarget |